Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PIC 060

Drug Profile

PIC 060

Latest Information Update: 28 Mar 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Procept
  • Class Antihyperglycaemics; Antipsoriatics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psoriasis; Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 28 Mar 2003 No development reported - Preclinical for Psoriasis in USA (PO)
  • 21 Feb 2000 Procept has merged with Heaven's Door Corporation to form HeavenlyDoor.com
  • 21 Feb 2000 Pacific Pharmaceuticals is now called Procept and has the biotechnology assets of the former Procept
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top